# OnCo record cytomx-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/cytomx-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "cytomx-therapeutics" ;
  schema:name "CytomX Therapeutics"@en ;
  schema:description "CytomX Therapeutics makes 'masked' antibody medicines: a peptide covers the antibody's binding site until tumour enzymes cut it off, so the drug switches on mainly inside tumours and can hit targets that healthy tissue also carries. Its lead, an EpCAM-directed topoisomerase inhibitor conjugate for advanced bowel cancer, is in phase 1 with Fast Track status."@en ;
  schema:url <https://onco.cc/companies/cytomx-therapeutics/>, <https://cytomx.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://cytomx.com/>, <https://cytomx.com/pipeline/> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/melanoma/> ;
  onco:sections <https://onco.cc/fronts/adcs/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/masked-adc/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/cytokine-therapy/> ;
  onco:targets <https://onco.cc/targets/cd3/> .